Top-Rated Stocks NASDAQ:XNCR Xencor - XNCR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $27.89 +0.49 (+1.79%) (As of 03/31/2023 05:17 PM ET) Add Compare Share Share Today's Range$27.50▼$28.2450-Day Range$26.86▼$36.9552-Week Range$19.35▼$38.20Volume342,173 shsAverage Volume390,221 shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$46.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Xencor MarketRank™ ForecastAnalyst RatingBuy3.09 Rating ScoreUpside/Downside66.4% Upside$46.13 Price TargetShort InterestBearish8.58% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment1.02Based on 5 Articles This WeekInsider TradingSelling Shares$739,628 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.80) to ($2.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector310th out of 1,009 stocksPharmaceutical Preparations Industry136th out of 494 stocks 4.5 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.13, Xencor has a forecasted upside of 66.4% from its current price of $27.72.Amount of Analyst CoverageXencor has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.58% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Xencor has recently increased by 13.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 2.8 News and Social Media Coverage News SentimentXencor has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Xencor this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $739,628.00 in company stock.Percentage Held by InsidersOnly 4.23% of the stock of Xencor is held by insiders.Percentage Held by Institutions98.99% of the stock of Xencor is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to decrease in the coming year, from ($2.80) to ($2.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -29.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -29.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xencor (NASDAQ:XNCR) StockXencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.Read More Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Stock News HeadlinesMarch 14, 2023 | finance.yahoo.comXencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023March 14, 2023 | finance.yahoo.comStrength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?March 31, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 28, 2023 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Analysts Just Trimmed Their Revenue Forecasts By 13%February 25, 2023 | finance.yahoo.comXencor Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 23, 2023 | finance.yahoo.comXencor (XNCR) Reports Q4 Loss, Tops Revenue EstimatesFebruary 23, 2023 | finance.yahoo.comXencor Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 16, 2023 | finance.yahoo.comXencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023March 31, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 7, 2023 | finance.yahoo.comXencor to Present at the SVB Securities Global Biopharma ConferenceJanuary 26, 2023 | finance.yahoo.comWhy Shares of Zencor Rose This WeekJanuary 9, 2023 | finance.yahoo.comXencor Highlights 2023 Corporate Priorities and Provides Portfolio UpdatesJanuary 5, 2023 | finance.yahoo.comCaris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug CandidatesJanuary 4, 2023 | finance.yahoo.comXencor to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 12, 2022 | finance.yahoo.comXencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual MeetingNovember 30, 2022 | finance.yahoo.comDoes Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect?November 25, 2022 | finance.yahoo.comXencor (XNCR) Upgraded to Buy: Here's What You Should KnowNovember 10, 2022 | finance.yahoo.comXencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual MeetingNovember 10, 2022 | finance.yahoo.comCan Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?November 6, 2022 | msn.comXencor Earnings PreviewNovember 3, 2022 | finance.yahoo.comXencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual MeetingNovember 1, 2022 | finance.yahoo.comXencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022October 20, 2022 | nasdaq.comPeek Under The Hood: SLYG Has 37% Upside - NasdaqOctober 20, 2022 | finance.yahoo.comSpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Begun - Yahoo FinanceOctober 19, 2022 | finance.yahoo.com24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight - Yahoo FinanceOctober 17, 2022 | businesswire.comBiocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022 - Business WireOctober 15, 2022 | money.usnews.comXencor IncSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Company Calendar Last Earnings2/23/2023Today3/31/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees254Year FoundedN/APrice Target and Rating Average Stock Price Forecast$46.13 High Stock Price Forecast$59.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+65.4%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,180,000.00 Net Margins-33.53% Pretax Margin-33.12% Return on Equity-7.47% Return on Assets-6.51% Debt Debt-to-Equity RatioN/A Current Ratio10.58 Quick Ratio10.58 Sales & Book Value Annual Sales$164.58 million Price / Sales10.17 Cash FlowN/A Price / Cash FlowN/A Book Value$12.14 per share Price / Book2.30Miscellaneous Outstanding Shares60,030,000Free Float57,491,000Market Cap$1.67 billion OptionableOptionable Beta0.82 Key ExecutivesBassil I. DahiyatPresident, Chief Executive Officer & DirectorJohn J. KuchChief Financial Officer & Senior Vice PresidentJohn R. DesjarlaisChief Scientific Officer & Senior VP-ResearchAllen YangChief Medical Officer & Senior Vice PresidentCelia EckertSecretary, Senior Vice President & General CounselKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDSchrödingerNASDAQ:SDGRAurinia PharmaceuticalsNASDAQ:AUPHPliant TherapeuticsNASDAQ:PLRXCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsBassil I DahiyatSold 2,602 sharesTotal: $77,747.76 ($29.88/share)Allen YangSold 1,094 sharesTotal: $32,688.72 ($29.88/share)Celia EckertSold 711 sharesTotal: $21,244.68 ($29.88/share)Bassil I DahiyatSold 5,831 sharesTotal: $183,210.02 ($31.42/share)Allen YangSold 4,069 sharesTotal: $127,847.98 ($31.42/share)View All Insider TransactionsView All Institutional Transactions XNCR Stock - Frequently Asked Questions Should I buy or sell Xencor stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price forecast for 2023? 11 brokers have issued 1 year price targets for Xencor's shares. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they expect the company's share price to reach $46.13 in the next year. This suggests a possible upside of 65.4% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2023? Xencor's stock was trading at $26.04 at the start of the year. Since then, XNCR stock has increased by 7.1% and is now trading at $27.89. View the best growth stocks for 2023 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, February, 23rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.63. The biopharmaceutical company earned $21.61 million during the quarter, compared to analyst estimates of $19.24 million. Xencor had a negative trailing twelve-month return on equity of 7.47% and a negative net margin of 33.53%. The business's revenue for the quarter was down 86.0% on a year-over-year basis. During the same period last year, the company posted $1.21 EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Raymond James SB-1 Equity ETF (RYJ) and SPDR S&P Biotech ETF (XBI). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." Who are Xencor's major shareholders? Xencor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include T. Rowe Price Investment Management Inc. (6.23%), Price T Rowe Associates Inc. MD (5.37%), Dimensional Fund Advisors LP (2.11%), Geode Capital Management LLC (1.89%), Norges Bank (0.90%) and Morgan Stanley (0.81%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch and John S Stafford III. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $27.89. How much money does Xencor make? Xencor (NASDAQ:XNCR) has a market capitalization of $1.67 billion and generates $164.58 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. How many employees does Xencor have? The company employs 254 workers across the globe. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350. This page (NASDAQ:XNCR) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.